Ulcus vulvae acutum Lipschütz in two young female patients

2014 ◽  
Vol 24 (3) ◽  
pp. 361-364 ◽  
Author(s):  
Ágnes Kinyó ◽  
Nikoletta Nagy ◽  
Judit Oláh ◽  
Lajos Kemény ◽  
Zsuzsanna Bata-Csörgő
2018 ◽  
Vol 9 (1) ◽  
pp. 31-34
Author(s):  
Sadia Imdad ◽  
Pankaj Kumar Saha ◽  
Md Mustafizur Rahman ◽  
Md Mozammal Hoque ◽  
Krishna Pada Saha ◽  
...  

Solid pseudopapillary neoplasm of pancreas (SPN) is a rare entity; therefore proper diagnosis, evaluation and formulation of treatment protocols is difficult. The commonest presenting symptom is abdominal pain. This article presents a case of solid pseudopapillary neoplasm of pancreas in a 35 years old lady. A high index of clinical suspicion is necessary to suspect and diagnose SPN. This diagnosis should be borne in mind when young female patients present with a pancreatic mass.J Shaheed Suhrawardy Med Coll, June 2017, Vol.9(1); 31-34


2022 ◽  
pp. 56-60
Author(s):  
E. V. Uvarova ◽  
E. P. Khashchenko ◽  
S. O. Kyurdzidi

This review is addressing an urgent problem of diagnosis and treatment strategy of polycystic ovary syndrome in adolescent girls. We analysed data from modern literary publications on the epidemiology and classification of the disease, as well as the adaptation of general principles for the management of young female patients tailored to their age peculiarities. The effective treatment strategies for adolescent girls with PCOS depending on its type are presented. Today there are several contradictions associated with both the diagnosis and treatment of the disease in the medical community. Thus, the use of the well-known Rotterdam criteria makes it difficult to diagnose PCOS in adolescent girls, since the criteria do not take into account characteristic changes that occur during puberty. Such manifestations as acne, hirsutism, menstrual irregularities, high androgen levels and morphology of polycystic ovaries on pelvic ultrasound imaging should be assessed with due account for age, puberty, hormonal balance with an assessment of the ratio of LH (luteinizing hormone)/FSH (follicle-stimulating hormone) and Free Androgen Index. There is no consensus in the medical community regarding the treatment strategy for PCOS. International communities have identified two main goals in the management of patients: normalization of menstrual function and improvement of the patients’ quality of life by preventing clinical symptoms of hyperandrogenism, and metabolic disorders of hyperplastic processes in target organs.Our analysis of objective scientific data showed that modern monophasic combined oral contraceptives (COCs) supplemented by of a folate component should be used to treat young female patients with PCOS, hyperandrogenism and psychosomatic disorders.


2017 ◽  
Vol 44 (1) ◽  
pp. 34-41 ◽  
Author(s):  
Joo Hyun Oh ◽  
Chae Min Kim ◽  
Seung Yong Song ◽  
Jae Sun Uhm ◽  
Dae Hyun Lew ◽  
...  

2018 ◽  
Vol Volume 10 ◽  
pp. 653-661 ◽  
Author(s):  
Lijun Shen ◽  
Miao Mo ◽  
Leon Jia ◽  
Huixun Jia ◽  
Qingguo Li ◽  
...  

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
abdelmonem awad ali ◽  
hassan seweny ◽  
mohammed mohammed ◽  
ahmed nawar

Author(s):  
Karen Lisa Smith ◽  
Clarisa Gracia ◽  
Anna Sokalska ◽  
Halle Moore

Female patients of reproductive age with cancer often require treatment that can compromise their future fertility. Treatment-related infertility is an important cancer survivorship issue and is associated with depression and diminished quality of life. Recent advances in reproductive health care provide the opportunity to preserve fertility prior to the initiation of cancer therapy. Clinical guidelines recommend that oncology providers counsel patients about the risk of treatment-related infertility and fertility preservation options, and that they refer those who are interested in fertility preservation to fertility specialists. Guidelines endorse the use of assisted reproductive techniques (ART) provided by reproductive endocrinologists to preserve fertility in young female patients with cancer. In addition, ovarian suppression with gonadotropin-releasing hormone (GnRH) agonists may be considered for ovarian protection during chemotherapy. This article reviews currently available and emerging ART for fertility preservation in female patients of reproductive age with cancer and current data supporting the use of ovarian suppression for ovarian protection during chemotherapy in this population. We also review the uptake of fertility services and discuss barriers to fertility preservation in female patients of reproductive age with cancer.


2013 ◽  
Vol 8 (1) ◽  
Author(s):  
Gang Li ◽  
Zhiguo Zhang ◽  
Tianbo Jin ◽  
Hongjuan Liang ◽  
Yanyang Tu ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Mirelle E. E. Bröker ◽  
Jan N. M. Ijzermans ◽  
Susanna M. van Aalten ◽  
Robert A. de Man ◽  
Türkan Terkivatan

Because of the risk of hormone-induced growth and spontaneous rupture of hepatocellular adenoma (HCA) during pregnancy, special considerations are required. Due to the scarcity of cases, there is no evidence-based algorithm for the evaluation and management of HCA during pregnancy. We think it should be questioned if it is justified to discourage pregnancy in all women with HCA. The biological behavior of this benign lesion might be less threatening than presumed and a negative advice concerning pregnancy has great impact on the lives of these young female patients. The balance between the pros and cons of hepatic adenomas and pregnancy should be reconsidered. In our center, pregnancy in women with an HCA up to 5 cm is no longer discouraged in close consultation with the patient, her partner, and members of the liver expert team.


Sign in / Sign up

Export Citation Format

Share Document